ZyVersa Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $388.60K
- P/E (TTM)
- –
- Dividend yield
- –
About ZyVersa Therapeutics
Pharmaceutical Preparations, SIC 2834
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with chronic renal and inflammatory diseases with high unmet medical needs. The company operates two proprietary drug development platforms discovered by researchers at the University of Miami: VAR 200, an injectable cholesterol efflux mediator in clinical development for chronic glomerular disorders including focal segmental glomerulosclerosis, Alport syndrome, and diabetic kidney disease; and IC 100, a monoclonal antibody inflammasome ASC inhibitor in preclinical development targeting chronic inflammatory conditions, led by cardiometabolic disorders associated with obesity. Its prospective patient populations include individuals suffering from rare kidney disorders and inflammatory diseases.
The company operates primarily within the United States while pursuing international collaborations to expand development and commercialization abroad. ZyVersa Therapeutics is headquartered in Lighthouse Point, Florida, where it maintains its principal executive offices.
Summary of the business section of ZyVersa Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- ZyVersa Therapeutics, Inc.
- Headquarters
- Lighthouse Point, FL
- Address
- 2436 North Federal Highway, Suite 466 33064
- Phone
- (908) 370-5102
- Website
- zyversa.com
- Employees
- 2,800,000, Dec 31, 2023
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, New York, NY
Stock & identifiers
- Ticker
- ZVSA
- Exchange
- OTC
- IPO date
- Dec 22, 2021
- Shares outstanding
- 8M, May 11, 2026
- Public float
- $3.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Apr 26, 2024; 1-for-35 reverse, Dec 5, 2023
- SEC CIK
- 1859007
- CUSIP
- 98987D300
- ISIN
- US98987D3008
- EIN
- 86-2685744
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Stephen C. Glover | Chief Executive Officer, Director | 578,198 |
| Karen A. Cashmere | Chief Commercial Officer | – |
| Pablo A. Guzman | Chief Medical Officer | 26,021 |
| Peter Wolfe | Chief Financial Officer | 44,585 |
| James Sapirstein | Director | – |
| Gregory Gene Freitag | Director | – |
| Min-Chul Park | Director | – |
| Robert G. Finizio | Director | – |
Employees
Headcount reported in annual reports
“Based on current estimates, MS affects 1 million people in the United States and 2.8 million people worldwide, according to data from the National Multiple”
Corporate history
Events identified from SEC filings